The osteoprotegerin/receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand system in cartilage

H Komuro, T Olee, K Kühn, J Quach… - … : Official Journal of …, 2001 - Wiley Online Library
Objective The receptor activator of nuclear factor κB (RANK) is a member of the tumor
necrosis factor receptor family. It is activated by the secreted or cell surface–bound RANK …

[引用][C] The role of osteoprotegerin and receptor activator of nuclear factor κB ligand in the pathogenesis and treatment of rheumatoid arthritis

LC Hofbauer, AE Heufelder - Arthritis & Rheumatism: Official …, 2001 - Wiley Online Library
The skeletal complications of rheumatoid arthritis (RA) include focal bone erosions and
juxtaarticular osteopenia at sites of active inflammation, as well as systemic osteopenia …

The expression of RANKL and OPG in the various grades of osteoarthritic cartilage

AR Upton, CA Holding, AA Dharmapatni… - Rheumatology …, 2012 - Springer
The objective of the study was to determine whether cartilage expression of the bone
regulating molecules receptor activator of nuclear factor κB ligand (RANKL) and …

[引用][C] The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: new insights from animal models

E Neumann, S Gay… - Arthritis & Rheumatism …, 2005 - Wiley Online Library
Rheumatoid arthritis (RA) is characterized by inflammatory synovitis and progressive
destruction of cartilage and bone. While the mechanisms of cartilage destruction in RA have …

Biology of RANK, RANKL, and osteoprotegerin

BF Boyce, L Xing - Arthritis research & therapy, 2007 - Springer
The discovery of the receptor activator of nuclear factor-κB ligand (RANKL)/RANK/
osteoprotegerin (OPG) system and its role in the regulation of bone resorption exemplifies …

Cytokine‐controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: Fibroblast‐mediated pathologic bone resorption

M Tunyogi‐Csapo, K Kis‐Toth… - … : Official Journal of …, 2008 - Wiley Online Library
Objective To determine whether proinflammatory cytokine treatment or the complete
absence of select cytokines modulates the expression of RANKL and osteoprotegerin (OPG) …

RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases

M Baud'Huin, F Lamoureux, L Duplomb… - Cellular and molecular …, 2007 - Springer
1997 saw the identification of a novel set of proteins within the tumor necrosis factor
(TNF)/TNF receptor families that are required for the control of bone remodeling. Therefore …

Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis

E Romas, NA Sims, DK Hards, M Lindsay… - The American journal of …, 2002 - Elsevier
Rheumatoid arthritis is characterized by progressive synovial inflammation and joint
destruction. While matrix metalloproteinases (MMPs) are implicated in the erosion of …

Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint

DR Haynes, TN Crotti, M Loric, GI Bain, GJ Atkins… - …, 2001 - academic.oup.com
Objective. This study investigated the involvement of the recently identified regulators of
osteoclast formation RANKL [receptor activator of nuclear factor kappaB (RANK) ligand …

Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand mRNA expression in patients with rheumatoid arthritis and healthy controls.

A Vanderborght, L Linsen, M Thewissen… - The Journal of …, 2004 - jrheum.org
OBJECTIVE: To further understand the role of osteoprotegerin (OPG) and receptor activator
of nuclear factor-kappaB ligand (RANK-L) in rheumatoid arthritis (RA), we studied the levels …